ROCHE Pharmaceuticals Xeloda
(capecitabine) is now available on
the Pharmaceutical Benefits Scheme
in combination with oxaliplatin for
the treatment of metastatic colorectal
cancer, and in combination with a
cisplastin-based regimen for the
treatment of advanced
oesophagogastric cancer.
Xeloda is an oral alternative to the
intravenous chemotherapy fluorouracil.The above article was sent to subscribers in Pharmacy Daily's issue from 30 Aug 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Aug 10
STRONG growth in Australia has helped MedAdvisor Solutions achieve robust results for FY24, with a revenue increase of 24.6% on the previous corresponding period to $122.1 million.
WESFARMERS has today reported strong growth in revenue across its Health division and its Australian Pharmaceutical Industries (API) subsidiary, despite a significant reduction in COVID-19 anti-viral product sales.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.